– In a national multicenter cohort of 6,341 pregnancies in women with relapsing‑onset MS, DMT management during pregnancy increased relapse rates during gestation and postpartum.
– The highest excess relapse risk was seen after prolonged natalizumab interruption and with fingolimod exposure before pregnancy.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
